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To investigate the association between the type of surgical intervention used to treat 
trochanteric hip fractures and 30-day mortality. 
Patients and Methods 
Analysis of data from the National Hip Fracture Database collected 1/1/2011-31/12/2014, 
using generalised linear models with incremental case-mix adjustment (patient, non-surgical 
and surgical characteristics and socioeconomic indicators). 82,990 patients with trochanteric 
hip fractures were included.  
Results 
Short and long intramedullary nails were associated with an increase in 30-day mortality 
(adjusted OR 1.125 [95% CI: 1.040, 1.218]; p=0.004) compared to sliding hip screws (12.5% 
increase). If this were causative, it would represent 98 excess deaths over the 4 year study 
period and one excess death would be caused by treating 112 patients with an 
intramedullary nail rather than a sliding hip screw.  
Conclusions 
There is a 12.5% increase in the odds of 30-day mortality associated with the use of 
intramedullary nails to treat trochanteric hip fractures compared to sliding hip screws.  
 
Clinical Relevance:  
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• Due to the association with lower mortality, sliding hip screws should be used in 
preference to intramedullary devices to treat trochanteric hip fractures, other than 
for particular fracture subtypes (e.g. pathological and atypical fractures).  
• Further randomised controlled trials comparing intramedullary and extramedullary 
devices should not be performed unless they are adequately powered to detect a 




Approximately 65,000 hip fractures occur annually in the NHS1 with a total cost of £2 to 3 
billion.2 1.6 million hip fractures occur worldwide annually which could rise to 6 million by 
2050.3 Hip fracture treatment aims to efficiently restore function and relieve pain with the 
lowest possible risk of morbidity and mortality.  
Trochanteric fractures represent between one third and one half of hip fractures.1,4,5 There 
is controversy regarding treatment. Some authorities recommend an extramedullary device 
(e.g. sliding hip screw; SHS),6 others recommend that either a SHS or intramedullary nail 
(IMN) can be used7 and some recommend the use of IMN (e.g. cephalomedullary nails) in all 
but the most simple and stable of fractures.8 IMN can be short or long. Long IMN are 
preferentially selected for the treatment of certain fracture subtypes (e.g. pathological and 
atypical) to provide fixation along the whole bone. A recent Cochrane review suggests a 
lower complication rate for SHS compared to IMN with equivalent functional outcomes and 
no difference in mortality.9 Despite this, the use of the more expensive IMNs6 has 
increased.10 
Publications concerning hip fractures have tended to disregard published clinical trial 
evidence.11 Studies to date have been underpowered to establish a difference in mortality. 
We hypothesised that there may be an association between the use of extramedullary (SHS) 
versus intramedullary devices (IMN) for the treatment of trochanteric hip fractures and 30-
day mortality due to the instrumentation of the femoral intramedullary canal. To obtain a 
large enough sample size to determine if this was the case, the National Hip Fracture 
Database (NHFD), a large and comprehensive national database of patients with a hip 
fracture and case ascertainment rates of over 95%, was studied.  
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PATIENTS AND METHODS 
Using data from the NHFD, we investigated the 30-day mortality rates associated with 
trochanteric fracture treatment with either an SHS, long IMN or short IMN. Patients 
admitted to a hospital in England and Wales during 2011 to 2014 were included. 
Data Source and Population 
The NHFD began data collection in 2007 and since January 2011, data capture is estimated 
to have been over 95%.12 Patients’ details with traceable National Health Service (NHS) 
numbers were passed by Crown Informatics (NHFD data processor) to the NHS Personal 
Demographics Service, who provided the date of death from the Office for National 
Statistics (ONS). Anonymised data were then passed to the research team. 
All individuals admitted with a trochanteric hip fracture between the 1st January 2011 and 
the 31st December 2014 that underwent surgery within 30-days of admission (or date of 
fracture if already an inpatient) and mortality status at 30-days were included. Exclusions 
were: Intracapsular and subtrochanteric fractures; surgical interventions other than SHS or 
IMN; unknown time to surgery; length of stay; time to surgery <0 hours or >30-days; length 
of stay <0 hours; unknown discharge destination; age <60 and >120 years; unknown age, 
gender and residence prior to admission (figure 1). 
The primary outcome is death at 30-days following trochanteric hip fracture. Deaths 
occurring prior to 30-days were determined using a combination of Office for National 
Statistics death records, and/or time of discharge/discharge destination, which also 
indicates when a patient has died. Contralateral hip fractures in the same patient were 
considered independent events. 
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The primary exposure was the type of surgical intervention received: Sliding hip screw (SHS), 
short intramedullary nail (IMN) or long IMN. 
All analyses were adjusted for the month and year of admission4,13 using month and year 
indicator variables respectively, due to the strong association between mortality and 
season.4 Models also included patient-level (Sunday surgery, time to surgery, out of hours 
surgery, age, sex, pre-admission residence, American Society of Anesthesiologists (ASA) 
grade, pre-operative abbreviated mental test score (AMTS), pathological fracture, pre-
operative mobility), non-surgical treatment (falls assessment, multi-disciplinary team (MDT) 
assessment), perioperative (anaesthetic type) and socioeconomic confounding factors 
(Supplementary Material Table 1). 
Statistical Analysis 
Means, standard deviations, and interquartile points were used to describe continuous 
variables. Frequencies and percentages were used to describe categorical variables. The 
associations between 30-day mortality and surgical intervention were modelled using 
logistic regression. Confounder adjustment was conducted incrementally (Table 1). Model 0 
was unadjusted. Model 1 adjusted for patient-level confounding factors. Model 2 further 
adjusted for non-surgical treatment factors, model 3 further adjusted for perioperative 
factors and model 4 further adjusted for socioeconomic position. Given the strength of the 
seasonal association with mortality, we used a wide variety of seasonal model specifications 
to investigate the primary effect’s sensitivity to these assumptions using two alternative 
seasonal specifications, an elapsed month parameterisation and a trigonometric regression 
(Fourier series).14,15 Data were examined for interactions between the primary exposure and 
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ASA grade and gender. All analyses were conducted in Stata 14.0 (StataCorp LP, College 
Station, TX). 
Missing data 
There were 52,481 complete cases available. Assuming the data were missing at random, 
we imputed missing values using multiple imputation with chained equations (MICE; 
Supplementary Material Table 2). Sex-specific imputation models were used for each 
variable that contained missing data, and combined prior to analysis. One hundred sex-
specific imputed data sets were generated with a burn-in of 30 repetitions. This allowed 
analysis of 82,990 cases in the models specified above. Complete case and multiple 




Between 1st January 2011 and 31st December 2014, there were 258,891 treatment episodes 
for hip fracture. Following application of inclusion/exclusion criteria, 82,990 cases were 
available for analysis (figure 1). 
26% of trochanteric fractures occurred in males, in whom the crude 30-day mortality rate 
was higher than females (10.6% vs. 6.7%). 86.7% of trochanteric fractures were treated with 
an SHS, 7.9% with a long IMN and 5.5% with a short IMN. For the NHFD, there has been a 
trend towards decreased use of SHS in trochanteric fractures (84% in 2011; 80% in 2016). 
The NHFD records substantial variation with 4% of patients receiving a SHS in some 
hospitals compared to 100% in others.16 Patient age, pre-operative AMTS and length of time 
to surgery were similar between the groups (Table 2), as were the type of residence patients 
were admitted from, overall condition (ASA grade), pre-operative mobility, whether MDT 
and falls assessment were conducted and type of anaesthesia (Table 3). As expected, a 
higher proportion of patients had a pathological fracture in the long IMN group (4.1%; 
n=187) compared to the SHS (0.6%; n=255) and short IMN groups (1.0%; n=29). When the 
crude length of stay was considered, in those alive at 30 days it was longest for long IMNs 
(median 18.2 days (interquartile range (IQR) 11.4,32.1)), than short IMNs (median 16.8 days 
(IQR 10.7,28.3)) and SHSs (median 16.5 days (IQR 10.1,29.1)) although these differences 
were small with wide variance.  
In the unadjusted analysis, the 30-day mortality was lowest for SHSs (7.6%), then short IMNs 
(8.2%) then long IMNs (8.3%). These differences persisted in logistic regression models, 
despite adjustment for patient, non-surgical treatment, perioperative and socioeconomic 
confounding factors (Table 4). The short and long IMN groups were combined for further 
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analysis. In crude analysis of complete case data, the use of IMN was associated with higher 
odds of death at 30-days (odds ratio (OR) 1.148 [95% CI: 1.046, 1.261]; p=0.004) compared 
with the use of SHS, this, albeit weaker association persisted after multiple imputation (OR 
1.092 [95% CI: 1.015, 1.175]; p=0.018) (Table 5). Following multiple imputation and 
adjustment for patient, non-surgical treatment, perioperative and socioeconomic 
confounding factors, again an association between IMN use and higher 30-day mortality 
was seen (OR 1.125 [95% CI: 1.040, 1.218]; p=0.004) compared with the use of SHS. The 
crude mortality of those treated with SHS is 7.63%, and assuming the OR increase in 
mortality due to the use of IM nails is 1.125 and the choice of intervention is causative, this 
would correspond to an excess of 98 deaths over the four years studied. Alternatively, the 
number of patients treated with IMN rather than SHS to cause one excess death would be 
112 if the choice of intervention is causative. 
The sensitivity analyses using elapsed month parameterisation and trigonometric regression 
did not alter the interpretation of any of the results (Supplementary Material Tables 3 and 
4). There was no interaction between the type of surgical intervention and ASA grade 




We have analysed 30-day mortality in patients who sustained a trochanteric hip fracture, 
treated with either a sliding hip screw or an intramedullary nail. In 82,990 hip fracture 
episodes between 1st January 2011 and the 31st December 2014, we have shown an 
association between the type of surgical intervention performed and the risk of 30-day 
mortality in both crude and adjusted analyses that, if the choice of intervention was 
causative, would equate to 25 excess deaths each year studied, despite the relatively low 
usage of IMN compared to other countries such as the USA. This difference, if there is 
causation, would equate to one excess death for every 112 patients treated with an IMN 
rather than a SHS; over the period studied 2,766 IMNs were used on average each year to 
treat trochanteric hip fractures in England and Wales. The differences observed were 
consistent across ASA grade and gender. This study is of a substantially larger population 
than has been included in 30 previous randomised controlled trials, which were not 
adequately powered to detect a difference in mortality outcomes.  
Given our findings, it is reassuring to note that 87% of trochanteric hip fractures in this 
cohort were treated with a SHS; however, from 2011 to 2016 there has been a decrease to 
75% nationally. There is significant unexplained national and global variation in practice.1,17 
Guidelines from the American Association of Orthopaedic Surgeons support the use of an 
IMN over a SHS to treat unstable trochanteric fractures (Arbeitsgemeinschaft für 
Osteosynthesefragen (AO) classification 31A2 and 31A3), and give equal recommendation to 
both treatments for stable trochanteric fractures (31A1). A survey of 3,784 orthopaedic 
surgeons in the USA revealed that only 19% primarily use a SHS for the treatment of 
trochanteric hip fractures,17 despite the proven cost effectiveness of the SHS.18 The decline 
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in use of the SHS has been well documented.19-21 Justification usually points towards 
theoretical biomechanical advantages associated with IM nailing, despite the lack of robust 
evidence to support this.9 It is difficult to determine the influence of industry and 
reimbursement practices19 on such a precipitous change in practice.  
Current guidance from the National Institute for Health and Care Excellence (NICE) in the UK 
states that a SHS should be used in preference to an IMN for trochanteric (AO classification 
31A1 and 31A2) fractures.22 A 2017 meta-analysis compared mortality between IMNs and 
SHSs to specifically treat more unstable 31A2 fractures (where any theoretical benefit of 
improved stability should be most marked between the interventions);23 four randomised 
controlled trials included reported one year mortality with pooled crude rates of 13% 
following 297 SHSs and 17% following 303 IM nails (relative risk 1.33 [95% CI: 0.92, 1.93] 
p=0.13).24-27 One-year mortality may not however represent a sensitive measure of the 
effect of the intervention in the frail, older population that sustain a hip fracture. A study of 
the patient case notes of those who had died within one year estimated that 33% of deaths 
were unrelated to the hip fracture, with only 25% being directly related.28 Mortality rates 
are seen to fall dramatically following an initial spike following hip fracture surgery.29 Thirty-
day mortality has been shown to provide a more discriminatory measure of surgical 
interventions in other studies of orthopaedic surgery in older people.30,31 Only one trial 
included within the 2017 meta-analysis reported mortality measured at 30-days. In this trial 
21% of 100 patients undergoing IMN had died at 30-days compared with 10% following 110 
SHS procedures (hazard ratio 1.69 [95% CI 0.91, 3.45], p=0.13).27 The data available in this 
study do not allow us to determine the cause of a difference in 30-day mortality rates 
between patients with trochanteric fractures treated with an IMN compared to a SHS. The 
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most obvious difference between the interventions is the instrumentation of the femoral 
intramedullary canal. We feel that the deleterious effects associated with this are the most 
likely cause of the observed difference in mortality. Intramedullary nailing is known to be 
associated with increased intramedullary pressure, embolic showers and fat intravasation,32 
features that the populations studied do not cope well with due to their poor physiological 
reserve. As increased pressures are observed, even with simple manoeuvres such as 
inserting guide wires,33 it is understandable that the effects may be common to short and 
long IMN, as we have observed here. The insertion of an IMN in these older individuals may 
represent a “second hit” during a vulnerable period physiologically.34 
The NHFD is a disease-specific national prospective audit with data capture rates over 95% 
in the period of study.12 These case ascertainment rates have continued to improve with the 
2017 NHFD annual report indicating that all eligible 177 hospitals contributed data, and in 
comparison to the Hospital Episodes Statistics database, which is generally considered the 
gold standard for case ascertainment in the NHS, ascertainment rates were 104% indicating 
under-reporting in HES. The dataset contains detailed information on patient, non-surgical 
treatment, perioperative and socioeconomic confounding factors that allow for relevant risk 
adjustment when outcomes such as 30-day mortality are considered. The number of 
mandatory fields for data collection, together with a Best Practice Tariff35 that encourages 
data capture ensures high rates of data capture. Despite the magnitude of the population 
studied, inferring causal effects from prospective observational data remains problematic 
and in this analysis, we are only able to determine an association, not causation.  
Although it is reassuring that the results of our adjusted analyses, with multiple imputation 
for missing variables, were consistent with the crude analysis and incremental adjustments, 
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we must remain cognisant of the limitations associated with the interpretation of cohort 
data. The NHFD does not capture data on the reasons motivating selection of surgical 
intervention; whether IMN are selected for individuals at higher overall risk of death is 
unknown (i.e. unknown confounding by indication); however, the variation in the pattern of 
usage across hospitals suggests hospital-level rather than patient-level characteristics may 
play a greater role. We did not have data on comorbidities to assess whether this 
assumption was correct. It is possible that adjustment for comorbidities, not available in the 
NHFD dataset beyond that provided by ASA grade, may have changed our results; however,  
this is unlikely given that scores used to predict mortality in hip fracture populations do not 
show greater discrimination when comorbidities are included rather than ASA.36 We 
observed a higher proportion of patients with pathological fractures treated with a long IM 
nail; this was expected and our model accounted for this variation. Classification of hip 
fractures in the NHFD is carried out by the treating surgical team and it is possible some 
fractures were misclassified. Another limitation is the dataset grouped all patterns of 
trochanteric fractures (AO/Orthopaedic Trauma Association (OTA) A1, A2 and A3 fractures) 
together, the current evidence regarding the treatment of A3 fractures, which represent a 
small subset (8% of trochanteric fractures), is inconclusive, and NICE recommends that 
either a SHS or IMN can be used. Currently there is no conclusive evidence to show that 
fracture patterns, that may be considered more severe, independently predict mortality in  
hip fracture populations. Accordingly, hip fracture mortality risk prediction scores do not 
include fracture type beyond the broad categorisation we have used.36,37 Our analysis 
studied 30-day mortality. We did not have data on cause of death which meant that we 
could not attempt to determine which deaths may have been associated with, or 
attributable to, the choice of surgical intervention. Other outcomes, such as length of stay, 
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rates of post-operative mobilization, peri-operative complications will be clinically relevant 
to healthcare providers and patients, but were beyond the scope of this analysis. Implant 
costs alone are 3 times higher for short IMN than SHS and over 4.5 times higher for long 
IMN than SHS.6 We do not have sufficient data to provide robust health economic estimates 
of differences between treatments. 
We have analysed data from a large and generalisable national cohort and have 
demonstrated a significantly elevated association with risk of death at 30-days in patients 
treated with both short and long intramedullary nails, compared to sliding hip screws for 
the treatment of trochanteric hip fractures. Therefore, the growing global trend towards 
increased use of intramedullary nails for the treatment of this common fracture type is not 
currently justified. We believe that a randomised controlled trial adequately powered for 
mortality would be difficult to deliver. To be adequately powered, with an alpha value of 
0.05, a power of 0.8 and an effect size of 0.1 on 30-day mortality are assumed, a simple 
design randomised controlled trial with a 1:1 allocation ratio would require a sample size of 
23,645 patients per group.  Alternative study designs, such as cluster randomised trials, may 
be appropriate for the study of these interventions in the hip fracture population with 
efficient data collection through routinely collected data sources such as the NHFD. Cluster 
designs would however have the effect of increasing the sample size when they account for 
variation between centres (or clusters). Patients, surgeons and other stakeholders need to 
be aware of the observed increased risk associated with intramedullary nails when selecting 
and commissioning operative interventions. Given the current lack of robust evidence to 
support the use of IMNs over SHSs for the treatment of trochanteric fractures and the 
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Table 1: Model specification detailing exposure and confounding variables used within the analysis 
Model Exposures Confounding variables 
0 a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
None 
1 Model 0: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
Patient Level confounding factors 
 
2 Model 1: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
Patient Level confounding factors 
Non-surgical treatment factors 
3 Model 2: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
Patient Level confounding factors 
Non-surgical treatment factors 
Surgical treatment factors 
4 Model 3: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
 
Patient Level confounding factors 
Non-surgical treatment factors 
Surgical treatment factors 
Socioeconomic position 
5 Sensitivity analysis; model 4: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
Patient Level confounding factors 
Non-surgical treatment factors 
Surgical treatment factors 
Elapsed month seasonal specification 
6 Sensitivity analysis; model 5: 
a) 3 implant groups (SHS, short IM nail, long IM nail) 
b) 2 implant groups (SHS, IM nail) 
Patient Level confounding factors 
Non-surgical treatment factors 
Surgical treatment factors 
Fourier series seasonal specification 
 
Definitions: Patient level confounding factors (Month of admission, Year of admission, Sunday Surgery, TTS - time to surgery[24 |>24] , Out of hours-<08:00 & >17:00, (Age [60 to 120], 
sex[male or female], pre-admission residence [own home, hospital, Nursing/rehabilitation/residential home], ASA grade[I+II, III, IV+V], Pre-operative AMTS score, Pathology[None, 
Malignancy, atypical], Pre-operative mobility [walks without aid, walks with aid, no functional mobility]). Non-surgical treatment factors (Falls assessment [yes/no], Multi-Disciplinary Team 
Assessment [yes/no]). Surgical treatment factors (Anaesthetics [Spinal, Spinal and epidural or nerve block, general anaesthetic, general anaesthetic + epidural or nerve block]. Socioeconomic 
position (Deciles of Income Deprivation Affecting Older People Index, Welsh Index Multiple Deprivation). 
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Table 2: Descriptive statistics of continuous variables  
    Alive @ 30days  Dead @ 30days 
  Fixation n Mean (SD)  [range]  n Mean (SD)  [range]  
Age at fracture 
(years) 
SHS 66,440 83.7 (8.3)  [60, 111]  5,486 87.1 (7.5)  [88, 107]  
Long IMN 5,973 82.4 (8.7)  [60, 104]  544 85.3 (8.1)  [87, 103]  
Short IMN 4,176 83.1 (8.3)  [60, 108]  371 86.8 (7.6)  [88, 104]  
All 76,589 83.5 (8.3)  [60, 111]  6,401 86.9 (7.5)  [87, 107]  
AMTS pre-
operatively 
SHS 55,914 6.87 (3.6)  [0, 10]  4,483 5.31 (3.9)  [6, 10]  
Long IMN 5,002 7.29 (3.4)  [0, 10]  449 6.06 (3.9)  [8, 10]  
Short IMN 3,457 7.08 (3.5)  [0, 10]  307 5.18 (3.9)  [6, 10]  
All 64,373 6.92 (3.6)  [0, 10]  5,239 5.37 (3.9)  [6, 10]  
Time to surgery 
(hours) 
SHS 66,440 30.3 (28.0)  [0.02, 691.9]  5,486 33.2 (30.6)  [24.5, 473.7]  
Long IMN 5,973 33.4 (29.8)  [0.42, 478.7]  544 37.9 (37.0)  [26.2, 384.8]  
Short IMN 4,176 30.2 (25.5)  [0.30, 363.3]  371 34.4 (31.3)  [25.0, 209.3]  
All 76,589 30.5 (28.0)  [0.02, 691.9]  6,401 33.7 (31.2)  [24.7, 473.7]  
Length of stay in 
hospital (days)* 
SHS 66,440 24.4 (181.7)  [0.1, 595.9]  5,486 12.3 (8.0)  [10.8, 30.0]  
Long IMN 5,973 26.3 (29.1)  [0.1, 1216.5]  544 12.9 (7.7)  [11.6, 30.0]  
Short IMN 4,176 23.1 (20.0)  [1.0, 183.6]  371 13.0 (10.7)  [11.2, 30.0]  
All 76,589 24.5 (169.5)  [0.1, 1216.5]  6,401 12.4 (8.1)  [10.8, 30.0]  
* Note – death in hospital triggers a discharge event and therefore those that die in hospital before 30 days may artefactually appear to have a 
shorter length of stay 
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Table 3: Descriptive statistics of categorical variables  
   Alive at 30 Days Dead at 30 days 
   SHS Long IMN Short IMN All SHS Long IMN Short IMN All 
    n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)  
Alive/Assumed Alive 66,440 (100.0) 5,973 (100.0) 4,176 (100.0) 76,589 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Dead 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5,486 (100.0) 544 (100.0) 371 (100.0) 6,401 (100.0) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Admitted from Hospital 2,557 (3.8) 194 (3.2) 152 (3.6) 2,903 (3.8) 400 (7.3) 35 (6.4) 26 (7.0) 461 (7.2) 
Nursing/ Residential 
Home / Rehabilitation 
Facility 14,329 (21.6) 1,044 (17.5) 795 (19.0) 16,168 (21.1) 1,729 (31.5) 147 (27.0) 118 (31.8) 1,994 (31.2) 
Own home* 49,554 (74.6) 4,735 (79.3) 3,229 (77.3) 57,518 (75.1) 3,357 (61.2) 362 (66.5) 227 (61.2) 3,946 (61.6) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
ASA Grade 1 1,197 (1.8) 78 (1.3) 96 (2.3) 1,371 (1.8) 19 (0.3) 2 (0.4) 1 (0.3) 22 (0.3) 
2 18,240 (27.5) 1,603 (26.8) 1,148 (27.5) 20,991 (27.4) 563 (10.3) 49 (9.0) 42 (11.3) 654 (10.2) 
3 36,686 (55.2) 3,324 (55.7) 2,256 (54.0) 42,266 (55.2) 2,990 (54.5) 285 (52.4) 201 (54.2) 3,476 (54.3) 
4 6,929 (10.4) 691 (11.6) 473 (11.3) 8,093 (10.6) 1,581 (28.8) 177 (32.5) 109 (29.4) 1,867 (29.2) 
5 132 (0.2) 10 (0.2) 8 (0.2) 150 (0.2) 52 (0.9) 5 (0.9) 4 (1.1) 61 (1.0) 
Missing 3,256 (4.9) 267 (4.5) 195 (4.7) 3,718 (4.9) 281 (5.1) 26 (4.8) 14 (3.8) 321 (5.0) 
Pathological 
fracture 
None 63,024 (94.9) 5,396 (90.3) 3,667 (87.8) 72,087 (94.1) 5,082 (92.6) 462 (84.9) 320 (86.3) 5,864 (91.6) 
Malignancy | Yes 385 (0.6) 246 (4.1) 42 (1.0) 673 (0.9) 65 (1.2) 41 (7.5) 9 (2.4) 115 (1.8) 
Atypical 267 (0.4) 37 (0.6) 29 (0.7) 333 (0.4) 22 (0.4) 6 (1.1) 2 (0.5) 30 (0.5) 
Missing 2,764 (4.2) 294 (4.9) 438 (10.5) 3,496 (4.6) 317 (5.8) 35 (6.4) 40 (10.8) 392 (6.1) 
Pre-operative 
Mobility 
Walks without aids 27,679 (41.7) 2,579 (43.2) 1,838 (44.0) 32,096 (41.9) 1,445 (26.3) 184 (33.8) 118 (31.8) 1,747 (27.3) 
Walks with aids 35,934 (54.1) 3,147 (52.7) 2,187 (52.4) 41,268 (53.9) 3,580 (65.3) 323 (59.4) 225 (60.6) 4,128 (64.5) 
No Functional Mobility 1,334 (2.0) 125 (2.1) 69 (1.7) 1,528 (2.0) 203 (3.7) 22 (4.0) 14 (3.8) 239 (3.7) 




No 2,014 (3.0) 246 (4.1) 154 (3.7) 2,414 (3.2) 434 (7.9) 61 (11.2) 30 (8.1) 525 (8.2) 
Yes 62,601 (94.2) 5,596 (93.7) 3,965 (94.9) 72,162 (94.2) 4,839 (88.2) 466 (85.7) 339 (91.4) 5,644 (88.2) 
Missing 1,825 (2.7) 131 (2.2) 57 (1.4) 2,013 (2.6) 213 (3.9) 17 (3.1) 2 (0.5) 232 (3.6) 
Specialist fall 
assessment 
Yes 62,043 (93.4) 5,505 (92.2) 3,963 (94.9) 71,511 (93.4) 4,851 (88.4) 469 (86.2) 342 (92.2) 5,662 (88.5) 
No Falls Assessment 3,869 (5.8) 429 (7.2) 201 (4.8) 4,499 (5.9) 578 (10.5) 73 (13.4) 28 (7.5) 679 (10.6) 




Spinal 19,241 (29.0) 1,513 (25.3) 1,115 (26.7) 21,869 (28.6) 1,605 (29.3) 136 (25.0) 104 (28.0) 1,845 (28.8) 
Spinal + (Epi | NB) 6,025 (9.1) 539 (9.0) 390 (9.3) 6,954 (9.1) 517 (9.4) 47 (8.6) 27 (7.3) 591 (9.2) 
GA 14,783 (22.3) 1,363 (22.8) 862 (20.6) 17,008 (22.2) 1,207 (22.0) 145 (26.7) 80 (21.6) 1,432 (22.4) 
GA + (Epi | NB) 17,360 (26.1) 1,764 (29.5) 1,176 (28.2) 20,300 (26.5) 1,406 (25.6) 149 (27.4) 111 (29.9) 1,666 (26.0) 
Other 932 (1.4) 131 (2.2) 52 (1.2) 1,115 (1.5) 44 (0.8) 11 (2.0) 1 (0.3) 56 (0.9) 
Missing 8,099 (12.2) 663 (11.1) 581 (13.9) 9,343 (12.2) 707 (12.9) 56 (10.3) 48 (12.9) 811 (12.7) 
*Includes sheltered housing.  
ASA = American Society of Anesthesiologists; Epi = epidural; NB = nerve block; GA = general anaesthetic 
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Table 4: Multivariate adjusted models with 3 groups for the effect of surgical interventions on 30-day mortality  
   Complete Case Analysis (n=52 481) Analysis after Multiple Imputation (n=82 990) 
Model Exposure OR (95% CI) P= OR (95% CI) P= 
0 
Sliding hip screw 1     1    
Intramedullary short nail 1.159 (1.008, 1.333) 0.038 1.076 (0.964, 1.201) 0.190 
Intramedullary long nail 1.141 (1.014, 1.284) 0.029 1.103 (1.006, 1.209) 0.037 
1 
Sliding hip screw 1     1    
Intramedullary short nail 1.202 (1.040, 1.389) 0.013 1.124 (1.004, 1.260) 0.043 
Intramedullary long nail 1.181 (1.043, 1.337) 0.009 1.133 (1.028, 1.248) 0.012 
2 
Sliding hip screw 1     1    
Intramedullary short nail 1.188 (1.027, 1.375) 0.020 1.115 (0.995, 1.250) 0.061 
Intramedullary long nail 1.146 (1.011, 1.298) 0.033 1.102 (1.000, 1.214) 0.051 
3 
Sliding hip screw 1     1    
Intramedullary short nail 1.188 (1.027, 1.375) 0.020 1.115 (0.995, 1.250) 0.061 
Intramedullary long nail 1.146 (1.011, 1.298) 0.033 1.110 (1.007, 1.224) 0.035 
4 
Sliding hip screw 1     1    
Intramedullary short nail 1.175 (1.015, 1.360) 0.030 1.121 (0.997, 1.260) 0.056 
Intramedullary long nail 1.145 (1.010, 1.297) 0.034 1.129 (1.020, 1.249) 0.019 
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Table 5: Multivariate adjusted models with 2 groups for the effect of surgical interventions on 30-day mortality  
   Complete Cases (n=52 481) Analysis after Multiple Imputation (n=82 990) 
Model Exposure OR (95% CI) P= OR (95% CI) P= 
0 
Sliding hip screw 1     1    
Intramedullary nail 1.148 (1.046, 1.261) 0.0037 1.092 (1.015, 1.175) 0.018 
1 
Sliding hip screw 1     1 
  
 
Intramedullary nail 1.190 (1.079, 1.312) 0.0005 1.129 (1.046, 1.219) 0.0018 
2 
Sliding hip screw 1     1 
  
 
Intramedullary nail 1.163 (1.054, 1.283) 0.0026 1.107 (1.025, 1.196) 0.0093 
3 
Sliding hip screw 1     1 
  
 
Intramedullary nail 1.163 (1.054, 1.283) 0.0026 1.112 (1.030, 1.201) 0.0066 
4 
Sliding hip screw 1     1 
  
 






Figure 1: Patient inclusions/exclusions into the study. 
 
